Apimeds Pharmaceuticals US, Inc. develops non-opioid, biologic-based therapies for pain management as a clinical-stage biopharmaceutical company. Company news centers on Apitox, also referenced as LT-100, a pure honeybee venom biologic candidate for signs and symptoms of osteoarthritis, with historical approval in South Korea under the Apitoxin name.
Recurring updates also cover U.S. regulatory interactions, clinical-development planning, material agreements, shareholder voting and governance matters, capital-structure disclosures, and operating results. Apimeds has also announced ai² Futures Lab collaborations tied to evaluation of early-stage pharmaceutical assets and biopharma business development projects.
Apimeds Pharmaceuticals (NASDAQ:APUS) and Lōkahi Therapeutics said the FDA Division of Anesthesiology, Addiction Medicine and Pain Medicine confirmed a Type C meeting for LT-100 (Apitox) on May 4, 2026 via teleconference. The meeting follows a Type C request and aims to align on key development considerations for LT-100 in the U.S.
LT-100 is pure honeybee venom previously approved for marketing in South Korea; the developers are integrating historical data, performing manufacturing process enhancements, and seeking FDA alignment on the U.S. regulatory path.
Apimeds Pharmaceuticals (NYSE American: APUS) closed a $100 million PIPE financing and completed integration steps with MindWave Innovations, strengthening liquidity to advance late-stage non-opioid therapeutic programs toward clinical and regulatory milestones. As part of the integration, ~1,000 Bitcoin held by MindWave were transferred into a segregated, risk-managed treasury governed by a defined investment policy to pursue AI-driven yield generation while preserving capital. The company said further updates on clinical progress, treasury deployment, and integration will follow in coming weeks.
Apimeds (NYSE American: APUS) announced a merger with MindWave to combine Apimeds’ late-stage, non-opioid biologic portfolio (lead candidate Apitox) with MindWave’s AI-driven institutional Digital Asset Treasury platform. The transaction is supported by a concurrent PIPE of up to $100 million to fund Apimeds’ clinical programs and expand MindWave infrastructure. Apimeds completed its IPO in May 2025 and plans to transfer Apimeds assets into a wholly owned subsidiary post-closing. The combined company targets diversified revenue from biotechnology and digital-asset treasury services, including secure corporate Bitcoin wallets, AI-enhanced Bitcoin yield, and a validator ecosystem powered by $NILA.
Regulatory filings with the SEC and an Information Statement under Section 14(c) will follow; the release highlights integration, financing, listing, and bitcoin-volatility risks.
Apimeds (NYSE American: APUS) is expanding its ai² Futures Lab™ program through a new collaboration with the University of Idaho College of Business and Economics, starting Spring 2026. The program pairs University of Idaho MBA and student teams with Apimeds mentors to evaluate early-stage pharmaceutical assets, perform market and IP analysis, and develop commercial strategies.
The University of Idaho joins University of Alabama, University of San Diego and University of Oregon in the ai² Futures Lab network, which combines human insight with AI analytics to support biotech innovation and experiential learning.
Apimeds Pharmaceuticals (NYSE: APUS) announced a new collaboration between its ai² Futures Lab program and the University of Oregon’s Lundquist College of Business, beginning Winter 2026. The partnership will place student teams with Apimeds mentors to evaluate early-stage or shelved pharmaceutical assets, conduct market and IP analysis, and identify business strategies to advance patient care.
The University of Oregon is the third academic partner after the University of Alabama and University of San Diego. Apimeds says the program pairs human insight with AI-driven analytics to surface therapeutic opportunities and train future industry leaders.
Apimeds Pharmaceuticals (NYSE American: APUS) has expanded its ai² Future Labs program to include graduate students from the University of San Diego's Knauss School of Business. The program aims to identify promising pharmaceutical assets while developing future biopharmaceutical industry leaders.
Students will work with Apimeds mentors to evaluate development projects, gaining experience in market analysis, FDA regulations, clinical development, competitive positioning, IP, and commercialization planning. Top performers will be eligible for paid internships or consulting opportunities with Apimeds.
The collaboration represents Apimeds' commitment to fostering innovation through industry-academic partnerships and developing the next generation of biotech leaders.
Apimeds Pharmaceuticals (NYSE:APUS) has responded positively to the FDA's new draft guidance on non-opioid pain therapy development, viewing it as a potential catalyst for their lead program Apitox, which targets chronic osteoarthritis pain.
The FDA guidance offers increased flexibility in clinical trial requirements and opens pathways for expedited development, including the possibility of requiring only one well-controlled chronic pain trial with supporting evidence. The agency's openness to biomarkers and scientific justification could potentially accelerate Apitox's regulatory submission timeline.
Apimeds Pharmaceuticals (NYSE American: APUS) has launched its ai² Future Labs program in partnership with The University of Alabama's Culverhouse College of Business. The initiative connects university students with real-world biopharmaceutical strategy and business development projects, focusing on identifying and evaluating abandoned drug development projects with potential.
Through this program, students will gain hands-on experience in market analysis, FDA regulations, clinical development, and commercialization planning. Top-performing teams will be eligible for paid internships or consulting opportunities with Apimeds. The partnership marks the first of several planned academic collaborations under the ai² innovation platform.
Apimeds (NYSE American: APUS), a clinical-stage biopharmaceutical company developing Apitox, a bee venom-based therapeutic, has announced two significant leadership appointments. Dr. Susan Kramer joins as Senior Vice President of Development, bringing over 30 years of biopharmaceutical experience, including 18 years at Genentech. Brian Peters has been appointed as Head of the company's proprietary ai²™ division.
Dr. Kramer, who previously served as Executive VP of Development at Concentric Analgesics, will oversee all product development activities. Peters, former Chief Strategy & Insights Officer at Heller Agency, will lead the strategy and launch of the ai²™ platform. Both appointments follow Apimeds' recent IPO and aim to strengthen the company's operational leadership.
Apimeds Pharmaceuticals US (NYSE American: APUS) has successfully completed its Initial Public Offering (IPO), raising $13.5 million in gross proceeds through the sale of 3,375,000 common stock shares at $4.00 per share. The company's shares began trading on NYSE American under the symbol "APUS" on May 9, 2025.
The clinical-stage biopharmaceutical company is developing Apitox, an intradermally administered bee venom-based toxin with potential therapeutic applications. The IPO proceeds will fund a Phase III clinical trial in knee osteoarthritis, initiate corporate sponsorship studies in multiple sclerosis, support product manufacturing, and address working capital needs.
D. Boral Capital served as the sole book-running manager, with underwriters receiving a 45-day option to purchase up to 506,250 additional shares and warrants for up to 168,750 shares.